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Abstract
Background Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that presents clinicians
with a diagnostic challenge. The use of natriuretic peptides to exclude a diagnosis of HFpEF has been proposed. We sought
to compare HFpEF patients with N-terminal pro-brain natriuretic peptide (NT-proBNP) level above and below the proposed
cut-off.
Methods Stable patients (n = 30) with left ventricular (LV) ejection fraction ≥ 50% were eligible if they had a diagnosis of HF
according to the European Society of Cardiology diagnostic criteria. Characteristics of patients with NT-proBNP below
(≤125 pg/mL) and above (>125 pg/mL) the diagnostic criterion were compared.
Results There were 19 (66%) women with median age 54 years. Half were African American (16, 53%), and most were obese.
There were no significant differences in clinical characteristics or medication use between groups. LV end-diastolic volume
index was greater in high NT-proBNP patients (P = 0.03). Left atrial volume index, E/e0 ratio, and E/e0 ratio at peak exercise
were not significantly different between NT-proBNP groups. Peak oxygen consumption (VO2), VO2 at ventilatory threshold,
and ventilatory efficiency measures were impaired in all patients and were not significantly different between high and low
NT-proBNP patients.
Conclusions NT-proBNP was below the proposed diagnostic cut-off point of 125 pg/mL in half of this obese study cohort.
Cardiac diastolic dysfunction and cardiorespiratory fitness were not significantly different between high and low NT-proBNP
patients. These data indicate that excluding the diagnosis of HFpEF based solely on NT-proBNP levels should be discouraged.
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Background
Due to heterogeneity, the heart failure with preserved
ejection fraction (HFpEF) syndrome presents clinicians with
a diagnostic challenge. The recently updated 2016 European
Society of Cardiology (ESC) guidelines mandate an elevated
brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-
proBNP) to diagnose HF, departing from prior recommenda-
tions.1–5
Indeed, evidence cited in the guidelines on the diagnostic
utility of NP derives from patients with predominantly
systolic dysfunction.5–9 Studies on the diagnostic utility of
NP in HFpEF patients are conflicting.10–13 Moreover, elevated
NP levels do not predict the response to treatment among
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HFpEF patients and treatment response may be greatest in
patients with low NP levels.14,15
Aims
The aim of the current study was to determine whether an
NT-proBNP level below the ESC-recommended diagnostic
cut-off of 125 pg/mL excludes a diagnosis of HFpEF.
Methods
We included stable HFpEF outpatients who were enrolled
prospectively for a clinical trial (NCT02173548) as described
previously.16 Patients were eligible according to 2007 ESC
criteria,3 which did not mandate an elevated NP level for
diagnosis, and were excluded if they had recent (within
1 month prior) hospitalization or were unable to complete
cardiopulmonary exercise (CPX) testing.
Plasma NT-proBNP levels were determined using a Elecsys
proBNP II platform and a electrochemiluminescence
immunoassay ‘ECLIA’ (Roche Diagnostics, Indianapolis, IN,
USA). The assay reports a range of accuracy between 5 and
35 000 pg/mL. Patients were categorized as low or high
NT-proBNP levels based upon the 2016 ESC diagnostic cut-off5
of 125 pg/mL. All patients underwent maximal CPX according
to a conservative ramping treadmill protocol and achieved
a peak respiratory exchange ratio > 1.0 (preferably ≥1.1).17,18
Venous whole blood samples were drawn prior to CPX.
Serum was separated, and NT-proBNP level quantification
was conducted on the same day as blood sample acquisition.
Body composition was assessed via bioelectrical impedance
analysis (Quantum IV Body Composition Analyzer, RJL
Systems, Clinton, MI, USA) as previously described.19
Transthoracic Doppler echocardiography was performed
by a cardiologist according to current recommendations.20–22
Summary statistics are reported as median and inter-
quartile range (IQR). Comparisons between patients with high
and low NT-proBNP were conducted with the Mann–Whitney
U-test for continuous variables and Fisher’s exact test for
categorical variables. Spearman’s ρ was calculated to
determine whether NT-proBNP correlated with cardiac
structure or cardiorespiratory fitness. A two-sided P-value
<0.05 was considered statistically significant. All analyses
were conducted with SPSS 24.0 (IBM, Armonk, NY, USA).
Results
Table 1 summarizes characteristics of included patients. All
patients had New York Heart Association (NYHA) functional
class II (9, 30%) or III (21, 70%) symptoms. All patients were
obese except one that was overweight [body mass index
(BMI) of 27]. Median BMI was 42 (38–48) kg/m2. There were
no differences in fat mass, % fat mass, or fat mass index
between low and high NT-proBNP patients (P > 0.50 for each
measure). Clinical characteristics and medication use were
not different between patients with a low NT-proBNP and pa-
tients with a high NT-proBNP (P > 0.13 for each comparison)
(Table 1). Patients with low NT-proBNP reported greater
self-assessed activity levels compared with high NT-proBNP
patients (P = 0.02). Many patients with low NT-proBNP level
reported NYHA functional class III symptoms (9, 60%),
indicating marked limitation of physical activity.
All patients achieved a maximal effort during CPX as
measured by peak respiratory exchange ratio. Exercise time
during maximal CPX was shorter in patients with high
NT-proBNP levels compared with low NT-proBNP levels 7.2
vs. 9.5 min (P = 0.007) (Figure 1). Cardiorespiratory fitness
was significantly impaired in all patients. Peak oxygen
consumption (VO2) was 13.3 mL/kg/min (IQR, 11.7–17.2) and
16.0 mL/kg/min (IQR, 13.5–17.8) in the high and low
NT-proBNP groups, respectively (P = 0.19 for between-group
comparison). These achieved peak VO2 represented 49% and
64% of the value predicted based upon age, sex, and weight
(P = 0.12 for between-group comparison). Impairments were
also observed in VO2 at ventilatory threshold, peak O2 pulse,
and oxygen uptake efficiency slope for both high and low
NT-proBNP groups (Table 2).
Left ventricular (LV) end-diastolic and end-systolic
volume indices as well as left atrial volume index (each
adjusted for body surface area) were smaller in patients
with low NT-proBNP levels (Table 2). Stroke volume index
was smaller in low NT-proBNP patients. Median ratio of
early mitral inflow velocity to mitral annular early diastolic
tissue velocity (E/e0) was 12.6 (IQR, 8.3–18.4) and 11.3
(8.2–11.7) in the high and low NT-proBNP groups,
respectively.
Conclusions
Abnormalities of cardiac structure, cardiac diastolic
function, and cardiorespiratory fitness were present in this
cohort of mostly obese patients with HFpEF regardless of
NT-proBNP level. Clinicians should avoid excluding a
diagnosis of HFpEF in obese patients with a low NT-proBNP
level who otherwise meet diagnostic criteria. Future studies
should assess the prevalence of ‘low NP HFpEF’ in a more
diverse cohort.
The use of NP levels was first introduced as a requirement
for the diagnosis of HFpEF in the 2016 ESC HF guidelines.5
The mandate to assess NP levels departed from a prior
ESC consensus statement in 2007 and other recommended
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diagnostic approaches, which recommend optional use of
NPs.3,22 This mandate was included despite a lack of
evidence to support the diagnostic precision and accuracy
of NPs in patients with HFpEF. Indeed, the majority of
available data on the diagnostic utility of NPs are derived
from studies that were designed to identify LV systolic
dysfunction,6–9 mixed cohorts that included few patients
with HFpEF10 or reported conflicting results.11,12 The data
presented herein further challenge the use of NPs to rule
out HFpEF in overweight or obese patients with signs and
symptoms of HF and objective cardiac diastolic dysfunction
or elevated filling pressure.
However, while elevated NP levels have very high positive
predictive value for HFpEF, low NP levels have very low
negative predictive value in obese patients who otherwise
meet criteria for a diagnosis of HFpEF: in the cohort
presented here, 50% of patients of HFpEF diagnosed
according to strict Doppler echocardiographic or haemody-
namic criteria had NT-proBNP < 125 pg/mL and showed
severe impairment in exercise capacity associated with
7diastolic dysfunction.
Importantly, we enroled patients according to 2007 ESC
consensus statement criteria.3 Had we applied 2016 ESC
guideline criteria and mandated an elevated NT-proBNP level
to confirm diagnosis, 50% of patients in our cohort would no
longer be considered to have HFpEF and an alternative
diagnosis would have been pursued erroneously to explain
cardiac signs and symptoms.
Obesity is associated with low NP levels due to increased
adipose tissue.23 It is unclear whether our results will
generalize to non-obese cohorts. However, we did not find
any differences in fat mass between the high and low
NT-proBNP groups, suggesting that body composition alone
cannot explain our findings. We believe that our results
Table 1. Patient characteristics in the overall cohort and according to N-terminal pro-brain natriuretic peptide level
Characteristic
All patients
(n = 30)
NT-proBNP > 125 pg/mL
(n = 15)
NT-proBNP ≤ 125 pg/mL
(n = 15) P-value
Age (years, IQR) 54 (48–62) 58 (51–66) 54 (48–57) 0.23
Female gender (n [%]) 19 (66) 7 (47) 12 (80) 0.13
African American (n [%]) 16 (53) 8 (53) 8 (53) 1.0
Diabetes (n [%]) 23 (77) 13 (87) 10 (67) 0.39
Hypertension (n [%]) 30 (100) 15 (100) 15 (100) 1.0
Hyperlipidaemia (n [%]) 22 (73) 10 (67) 12 (80) 0.68
Shortness of breath (n [%]) 30 (100) 15 (100) 15 (100) 1.0
Orthopnoea (n [%]) 14 (50) 8 (57.1) 6 (42.9) 0.71
Paroxysmal nocturnal dyspnoea (n [%]) 6 (20) 3 (21.4) 3 (21.4) 1.0
Peripheral oedema (n [%]) 11 (37) 8 (57.1) 3 (21.4) 0.12
Systolic blood pressure (mm Hg) 130 (119–137) 130 (120–140) 125 (112–134) 0.35
Diastolic blood pressure (mm Hg) 70 (62–74) 70 (62–80) 68 (62–72) 0.33
Heart rate (beats/min) 75 (62–83) 63 (58–88) 78 (67–83) 0.25
C-reactive protein (mg/L) 6.1 (3.7–16.2) 6.9 (4.1–17) 4.6 (2.7–14.5) 0.38
Body composition
Body mass index (kg/m2, IQR) 42 (38–48) 42 (40–54) 42 (36–45) 0.22
Normal weight 1 (7) 1 (7) 0 0.26
Class 1 obesity (n [%]) 2 (13) 0 2 (13)
Class 2 obesity (n [%]) 8 (27) 3 (20) 5 (33)
Class 3 obesity (n [%]) 19 (63) 11 (73) 8 (53)
Fat mass (kg) 55 (47–61) 54 (43–63) 55 (49–59) 0.92
Fat mass (% total body weight) 48 (38–52) 40 (37–49) 50 (37–53) 0.50
Fat mass index 19 (16–23) 19 (15–23) 19 (17–23) 0.77
New York Heart Association functional class
Class II 9 (30) 3 (20) 6 (40) 0.43
Class III 21 (70) 12 (80) 9 (60)
Quality of life assessment (score [IQR])
MLHFQ 61 (35–73) 67 (44–74) 60 (27–67) 0.44
DASI 23 (16–33) 16 (11–27) 26 (19–40) 0.02
Heart failure therapies (n [%])
ACE-I or ARB 17 (57) 8 (53) 9 (60) 0.99
Beta-blocker 25 (83) 13 (87) 12 (80) 0.99
Aldosterone antagonist 17 (57) 8 (53) 9 (60) 0.99
Hydralazine 8 (27) 6 (40) 2 (13) 0.22
Nitrates 2 (7) 2 (13) 0 0.48
Loop diuretic 30 (100) 15 (100) 15 (100) 1.0
Loop diuretic dose (mg furosemide) 80 (40–160) 80 (40–160) 80 (20–160) 0.82
NT-proBNP (pg/mL, IQR) 127 (48–251) 248 (174–318) 48 (24–90) <0.001
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DASI, Duke Activity Status Index; IQR, inter-quartile
range; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NT-proBNP, N-terminal pro-brain natriuretic peptide.
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Figure 1 Cardiac structure and function and cardiorespiratory fitness according to N-terminal pro-brain natriuretic peptide (NT-proBNP) level for each
patient is presented. The vertical dashed line separates patients with NT-proBNP level above and below 125 pg/mL, the diagnostic cut-point
recommended by the European Society of Cardiology. E/e0 ratio, early diastolic mitral inflow velocity to mitral annular velocity ratio; LAVI, left atrial
volume index; LVEDVI, left ventricular end-diastolic volume index; OUES, oxygen uptake efficiency slope; pVO2, peak oxygen consumption.
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retain a high degree of relevance for population of patients
with HFpEF as obesity is an important and highly prevalent
co-morbidity in this group.24
These data, however, do not support elimination of NP
assessment as part of routine management of HFpEF
patients. Indeed, NPs remain strong markers of LV wall
stress25 and prognosis.26 Our own data indicate that
abnormalities in cardiac structure and cardiorespiratory
fitness are likely worse in patients with high NT-proBNP levels
compared with those with low NT-proBNP levels.
These results have important implications for the use of
elevated NP level as an inclusion criterion in clinical
trials.27–29 Our data support the use of a lower threshold
for inclusion compared with prior trials in order to enrol
patients with HFpEF and obesity. Of note, even many of the
patients in the high NT-proBNP group would have failed to
meet the inclusion criteria for recent HFpEF studies,30 and
thus overweight and obese patients are likely to be largely
under-represented in contemporary HFpEF study with
NT-proBNP-driven enrolment criteria.
Nevertheless, it should be noted that our study is limited
by a small sample size and by the single-time-point
determination of NT-proBNP. All patients had been treated
for HFpEF by the time of blood sampling and therefore it is
possible that untreated NT-proBNP levels would have been
higher in newly diagnosed patients, yet this is likely to occur
in clinical practice in which thiazide diuretics are commonly
used for the treatment of arterial hypertension. Finally, our
results may not generalize to other ethnicities or to normal
weight individuals. However, results similar to ours have
been reported previously in various settings.11–13
In summary, excluding the diagnosis of HFpEF based solely
on NT-proBNP levels should be discouraged in overweight
and obese patients.
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Table 2. Cardiac structure and function and cardiorespiratory fitness in the overall cohort and according to N-terminal pro-brain
natriuretic peptide level
Parameter
All patients
(n = 30)
NT-proBNP > 125 pg/mL
(n = 15)
NT-proBNP ≤ 125 pg/mL
(n = 15) P-value
Doppler echocardiography
LVEF (%) 60 (56–63) 60 (53–63) 60 (57–62) 0.78
LVEDV index (mL/m2) 46 (39–58) 52 (45–62) 43 (37–51) 0.03
LVESV index (mL/m2) 18 (14–26) 21 (16–30) 16 (14–21) 0.08
SV index (mL/m2) 29 (23–34) 30 (28–34) 24 (23–30) 0.02
LAV index (mL/m2) 30 (23–39) 30 (26–41) 26 (22–37) 0.35
E/A ratio 1.1 (0.9–1.4) 1.2 (0.9–1.6) 1.0 (0.9–1.2) 0.16
DT (ms) 230 (188–270) 230 (190–280) 229 (151–250) 0.31
e0 (cm/s) 7.9 (5.7–9.2) 6.2 (5–6.6) 7 (6.5–8.8) 0.05
E/e0 ratio 11.4 (8.5–13.1) 12.6 (8.3–18.4) 11.3 (8.2–11.7) 0.20
e0 at peak exercise (cm/s) 9.6 (8.4–12.1) 8.6 (7.7–10.6) 10.5 (9.6–13.3) 0.08
E/e0 ratio at peak exercise 11.5 (8.0–14.7) 12.4 (10.5–17.8) 10.5 (7.0–12.6) 0.10
Change in E/e0 with exercise 0.4 (1.1 to 2.1) 2.0 (0.9 to 3.3) 0.5 (2.5 to 1.6) 0.10
LV s0 (cm/s) 7.6 (6.9–8.5) 7.5 (6.2–8.5) 9.8 (9.4–11.3) 0.46
RV s0 (cm/s) 13 (9.6–14.6) 13.5 (9.8–15.5) 12.4 (9.6–13.5) 0.53
TAPSE (cm) 2.5 (2.0–2.7) 2.3 (2.0–2.9) 2.5 (2.2–2.6) 0.76
Cardiopulmonary exercise testing
Exercise time (min) 8.4 (6.4–10.1) 7.2 (5.4–8.4) 9.5 (8.3–11.0) 0.007
Peak respiratory exchange ratio 1.10 (1.04–1.15) 1.09 (1.04–1.15) 1.10 (1.03–1.16) 0.99
Peak VO2 (mL/kg/min) 13.9 (11.9–17.7) 13.3 (11.7–17.2) 16 (13.5–17.8) 0.19
Predicted peak VO2 (%) 51 (43–65) 49 (42–54) 64 (43–71) 0.12
Peak VO2 (L/min) 1.7 (1.4–2.1) 1.9 (1.5–2.2) 1.8 (1.4–2.2) 0.78
Predicted peak VO2 (%) 79 (67–88) 74 (63–82) 84 (67–101) 0.17
VO2 at VT (L/min) 1.41 (1.07–1.61) 1.44 (0.98–1.67) 1.38 (1.07–1.57) 0.81
Peak O2 pulse (mL/beat) 14.4 (11.0–16.5) 15.6 (11.5–17.7) 13.5 (10.8–15.7) 0.11
VE/VCO2 slope 29 (27–33) 30 (28–34) 28 (27–32) 0.31
OUES 2.23 (1.90–2.64) 2.25 (2.07–2.75) 2.18 (1.79–2.53) 0.20
Rating of perceived exertion 17 (15–17) 17 (15–17) 17 (15–18) 0.54
Borg dyspnoea score 7 (4–9) 7 (4–9) 7 (3–9) 0.51
DT, deceleration time; E, early diastolic mitral annular inflow velocity; e0, early diastolic mitral annular velocity; LAV, left atrial volume;
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; IQR, in-
ter-quartile range; OUES, oxygen uptake efficiency slope; RV, right ventricular; s0, peak systolic annular velocity; SV, stroke volume; TAPSE,
tricuspid annular plane systolic excursion VO2, oxygen consumption; VE/VCO2 slope, minute ventilation-carbon dioxide production slope;
VT, ventilatory threshold.
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